Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2010
Date:11/4/2010

CARLSBAD, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended September 30, 2010.  The Company finished the third quarter of 2010 with a pro forma net operating loss (NOL) of $6.0 million and $23.1 million for the three and nine months ended September 30, 2010, respectively, compared to a pro forma net operating loss of $6.9 million and $6.1 million for the same periods in 2009.  On a GAAP basis, Isis reported a loss from operations of $8.9 million and $32.5 million for the three and nine months ended September 30, 2010, respectively, compared to $10.4 million and $15.9 million for the same periods in 2009.  

"In 2010, our most notable accomplishment is the completion of two more positive Phase 3 studies of mipomersen.  The successful completion of the Phase 3 program for mipomersen to support our initial market brings us closer to the commercialization of a first-in-class drug for patients who are in desperate need of new therapies.  Genzyme is on track to file for marketing approval of mipomersen in both the U.S. and Europe in the first half of next year.  We believe that the initial market for mipomersen represents a significant financial opportunity, and we are excited to bring this new medicine to an underserved patient population," said B. Lynne Parshall, COO and CFO of Isis.  

"We continue to maintain a strong financial position in large part due to our partnership successes that have continued to generate new revenue for us.  For example, our 2010 revenue includes the amortization of upfront fees from our new collaboration with GSK and new sublicensing revenue from Regulus' alliance with sanofi-aventis.  In addition, we have earned $13 million in milestone payments from our partners.  We earned many of these mileston
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
(Date:1/23/2015)... a third of reproductive-aged women enrolled in Medicaid, and more ... prescription for an opioid pain medication each year during 2008-2012, ... Weekly Report (MMWR). Opioids are typically prescribed ... They are also found in some prescription cough medications. The ...
(Date:1/23/2015)... MERIDIAN, Idaho , Jan. 23, 2015  Now available ... Patent No. 7,849,611) support that prevents ankle sprains by ... a brace, it fits securely around the outside of ... ankle mobility & comfort while still offering protection against ...
Breaking Medicine Technology:Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... PARK, N.C., April 25, 2011 GlaxoSmithKline (GSK) announced ... has approved Lamictal® XR™ (lamotrigine) Extended-Release Tablets ... older with partial seizures taking one anti-epileptic drug. This ... XR which is already approved as add-on treatment ...
... eye doctors , Rockland Eye Physicians and Surgeons, one of ... use of Alcon,s cutting edge AcrySof IQ ReSTOR IOL available ... other cataract treatments in that it allows the ... the use of bifocals or trifocals in many situations. ...
Cached Medicine Technology:FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients 2FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients 3FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients 4FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients 5Renowned New York Ophthalmologists, Drs. Glen Weiss and Robert Chen of Rockland Eye Physicians Use the AcrySof IQ ReSTOR IOL to Correct Cataracts Without Glasses 2Renowned New York Ophthalmologists, Drs. Glen Weiss and Robert Chen of Rockland Eye Physicians Use the AcrySof IQ ReSTOR IOL to Correct Cataracts Without Glasses 3
(Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... no survival difference for those with, without device , WEDNESDAY, ... first weeks after a heart attack does not improve survival, ... cardiac arrest occurred among those given the devices, which shock ... was about the same as for those who did not ...
... Researchers identify possible genetic links, but urge further study ... and genomic regions that might be associated with autism ... The researchers identified a single-letter change on chromosome 5 ... to help guide the growth of neurons and their ...
... Each year, an estimated 800,000 Americans will ... the victims survive, but their lives, and those of ... victims can suffer from a multitude of problems, including ... sleep disturbances. , Careforward , an organization ...
... (NYSE: CRDA ; CRDB) European third party administration ... of Broadspire, a Crawford company, continuing the leading TPA,s ... CRDA ; CRDB), the world,s largest independent provider of ... Broadspire brand at the Federation of European Risk Management ...
... VIEW, Calif., Oct. 7 Satellite Healthcare, one of ... services and a major sponsor of nephrology research, today ... 21st Annual San Francisco Author,s Luncheon. , The ... year more than 1,200 people are captivated by the ...
... 7 Coverall Health-Based Cleaning System(SM), a leading franchisor of ... as one of the "50 Top Franchises for Minorities" ... third year in a row. The list of top ... Today, the national daily newspaper. Coverall was also honored ...
Cached Medicine News:Health News:Early Defibrillator After Heart Attack May Not Pay Off 2Health News:Early Defibrillator After Heart Attack May Not Pay Off 3Health News:Potential Pieces of Autism Puzzle Revealed 2Health News:Mingling, Martinis & Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 2Health News:Crawford & Company's Broadspire Unit Continues Its European Expansion 2Health News:Satellite Healthcare Partners With the National Kidney Foundation for the 21st Annual San Francisco Author's Luncheon 2Health News:Coverall Named Among '50 Top Franchises for Minorities' for Third Consecutive Year 2
ACE Control Serum provides the laboratory with vital information on the performance of the ACE chemistry assay....
Medical Claims Billing...
e-MDs Bill practice management system is used in the medical billing cycle....
BillingPro...
Medicine Products: